CAB-CD73

CAB-CD73 appears to refer to an experimental anti-CD73 therapeutic candidate, likely an antibody-based agent directed against ecto-5-prime-nucleotidase. CD73 catalyzes extracellular AMP to adenosine, a pathway that can promote tumor-associated immunosuppression, so CD73-directed agents are generally intended to reduce adenosine generation and enhance anti-tumor immune activity. However, publicly available evidence specifically identifying CAB-CD73 as a distinct, clinically characterized drug candidate is extremely limited, and the exact molecular format, developer attribution, clinical status, formulation, and indications could not be confirmed with confidence from accessible sources.